Molecular mechanisms involved in farnesol-induced apoptosis

被引:151
作者
Joo, Joung Hyuck [1 ]
Jetten, Anton M. [1 ]
机构
[1] Natl Inst Environm Hlth Sci, Cell Biol Sect, LRB, Div Intramural Res,NIH, Res Triangle Pk, NC 27709 USA
关键词
Farnesol; Apoptosis; Isoprenoid; Chemoprevention; Endoplasmic reticulum stress; Unfolded protein response; CTP:phosphocholine cytidylyltransferase; Nuclear receptor; Cancer; NF-kappa B; Apoptosome; MAP kinase; ENDOPLASMIC-RETICULUM STRESS; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; UNFOLDED PROTEIN RESPONSE; NF-KAPPA-B; PHASE-II TRIAL; ADMINISTERED; TIMES; ISOPRENOID-MEDIATED INHIBITION; AGENT PERILLYL ALCOHOL; LUNG-CARCINOMA CELLS; SMOOTH-MUSCLE-CELLS;
D O I
10.1016/j.canlet.2009.05.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The isoprenoid alcohol farnesol is an effective inducer of cell cycle arrest and apoptosis in a variety of carcinoma cell types. In addition, farnesol has been reported to inhibit tumorigenesis in several animal models suggesting that it functions as a chemopreventative and anti-tumor agent in vivo. A number of different biochemical and cellular processes have been implicated in the growth-inhibitory and apoptosis-inducing effects of farnesol. These include regulation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and CTP:phosphocholine cytidylyltransferase alpha (CCT alpha), rate-limiting enzymes in the mevalonate pathway and phosphatidylcholine biosynthesis, respectively, and the generation of reactive oxygen species. In some cell types the action of farnesol is mediated through nuclear receptors, including activation of farnesoid X receptor (FXR) and peroxisome proliferator-activated receptors (PPARs). Recent studies have revealed that induction of endoplasmic reticulum (ER) stress and the subsequent activation of the unfolded protein response (UPR) play a critical role in the induction of apoptosis by farnesol in lung carcinoma cells. This induction was found to be dependent on the activation of the MEK1/2-ERK1/2 pathway. In addition, farnesol induces activation of the NF-kappa B signaling pathway and a number of NF-kappa B target genes. Optimal activation of NF-kappa B was reported to depend on the phosphorylation of p65/RelA by the MEK1/2-MSK1 signaling pathway. In a number of cells farnesol-induced apoptosis was found to be linked to activation of the apoptosome. This review provides an overview of the biochemical and cellular processes regulated by farnesol in relationship to its growth-inhibitory, apoptosis-promoting, and anti-tumor effects. Published by Elsevier Ireland Ltd.
引用
收藏
页码:123 / 135
页数:13
相关论文
共 160 条
  • [1] DIFFERENCES IN SENSITIVITY TO FARNESOL TOXICITY BETWEEN NEOPLASTICALLY-DERIVED AND NON-NEOPLASTICALLY-DERIVED CELLS IN CULTURE
    ADANY, I
    YAZLOVITSKAYA, EM
    HAUG, JS
    VOZIYAN, PA
    MELNYKOVYCH, G
    [J]. CANCER LETTERS, 1994, 79 (02) : 175 - 179
  • [2] Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells
    Anthony, ML
    Zhao, M
    Brindle, KM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (28) : 19686 - 19692
  • [3] Involvement of ERK MAP kinase in endoplasmic reticulum stress in SH-SY5Y human neuroblastoma cells
    Arai, K
    Lee, SR
    van Leyen, K
    Kurose, H
    Lo, EH
    [J]. JOURNAL OF NEUROCHEMISTRY, 2004, 89 (01) : 232 - 239
  • [4] Ariazi EA, 1999, CANCER RES, V59, P1917
  • [5] Herbal isoprenols induce apoptosis in human colon cancer cells through transcriptional activation of PPARγ
    Au-Yeung, Kathy Ka-Wai
    Liu, Po-Ling
    Chan, Cecilia
    Wu, Wing-Yee
    Lee, Susanna Sau-Tuen
    Ko, Joshua Ka-Shun
    [J]. CANCER INVESTIGATION, 2008, 26 (07) : 708 - 717
  • [6] A phase I trial of perillyl alcohol in patients with advanced solid tumors
    Azzoli, CG
    Miller, VA
    Ng, KK
    Krug, LM
    Spriggs, DR
    Tong, WP
    Riedel, ER
    Kris, MG
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (06) : 493 - 498
  • [7] A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days
    Bailey, HH
    Wilding, G
    Tutsch, KD
    Arzoomanian, RZ
    Alberti, D
    Feierabend, C
    Simon, K
    Marnocha, R
    Holstein, SA
    Stewart, J
    Lewis, KA
    Hohl, RJ
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (04) : 368 - 376
  • [8] A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group study E2E96
    Bailey, HH
    Levy, D
    Harris, LS
    Schink, JC
    Foss, F
    Beatty, P
    Wadler, S
    [J]. GYNECOLOGIC ONCOLOGY, 2002, 85 (03) : 464 - 468
  • [9] Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer
    Bailey, Howard H.
    Attia, Steven
    Love, Richard R.
    Fass, Terri
    Chappell, Rick
    Tutsch, Kendra
    Harris, Linda
    Jumonville, Alcee
    Hansen, Richard
    Shapiro, Gary R.
    Stewart, James A.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 149 - 157
  • [10] Belanger J T, 1998, Altern Med Rev, V3, P448